Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1981 AL 1995

Audio-biofeedback training for posture and balance in patients with Parkinson's disease

Mirelman A, Herman T, Nicolai S, Zijlstra A, Zijlstra W, Becker C, Chiari L, Hausdorff JM.

J Neuroeng Rehabil. 2011 Jun 21;8:35. doi: 10.1186/1743-0003-8-35.

Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"?

Martínez-Horta S, Kulisevsky J.

J Neural Transm (Vienna). 2011 Aug;118(8):1185-90. doi: 10.1007/s00702-011-0675-9. Epub 2011 Jun 22.

Subthalamic nucleus versus pedunculopontine nucleus stimulation in Parkinson disease: synergy or antagonism?

Ferraye MU, Debû B, Fraix V, Krack P, Charbardès S, Seigneuret E, Benabid AL, Pollak P.

J Neural Transm (Vienna). 2011 Oct;118(10):1469-75. doi: 10.1007/s00702-011-0673-y. Epub 2011 Jun 22.

Pre-operative evaluations for DBS in dystonia

Thobois S, Taira T, Comella C, Moro E, Bressman S, Albanese A.

Mov Disord. 2011 Jun;26 Suppl 1:S17-22. doi: 10.1002/mds.23481.

Early postoperative management of DBS in dystonia: programming, response to stimulation, adverse events, medication changes, evaluations, and troubleshooting

Kupsch A, Tagliati M, Vidailhet M, Aziz T, Krack P, Moro E, Krauss JK.

Mov Disord. 2011 Jun;26 Suppl 1:S37-53. doi: 10.1002/mds.23624.

A systematic review of the worldwide prevalence and incidence of Parkinson's disease

Muangpaisan W, Mathews A, Hori H, Seidel D.

J Med Assoc Thai. 2011 Jun;94(6):749-55.

Anorectal dysfunctions in Parkinson's disease

Kim JS, Sung HY, Lee KS, Kim YI, Kim HT.

J Neurol Sci. 2011 Nov 15;310(1-2):144-51. doi: 10.1016/j.jns.2011.05.048. Epub 2011 Jun 22.

Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish

Ren G, Xin S, Li S, Zhong H, Lin S.

PLoS One. 2011;6(6):e20630. doi: 10.1371/journal.pone.0020630. Epub 2011 Jun 16.

PET molecular imaging in stem cell therapy for neurological diseases

Wang J, Tian M, Zhang H.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1926-38. doi: 10.1007/s00259-011-1860-7. Epub 2011 Jun 23.

Enhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the network

Xu X, Warrington AE, Bieber AJ, Rodriguez M.

CNS Drugs. 2011 Jul;25(7):555-73. doi: 10.2165/11587830-000000000-00000.

Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease

Little JP, Villanueva EB, Klegeris A.

Mini Rev Med Chem. 2011 Jun;11(7):582-90. doi: 10.2174/138955711795906905.

Neuroregeneration in neurodegenerative disorders

Enciu AM, Nicolescu MI, Manole CG, Mureşanu DF, Popescu LM, Popescu BO.

BMC Neurol. 2011 Jun 23;11:75. doi: 10.1186/1471-2377-11-75.

Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients

Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K.

Sleep Med. 2011 Aug;12(7):711-3. doi: 10.1016/j.sleep.2011.01.015. Epub 2011 Jun 22.

Targeting NGF pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases

Colafrancesco V, Villoslada P.

Arch Ital Biol. 2011 Jun;149(2):183-92. doi: 10.4449/aib.v149i2.1376.

Neuroactive steroids: focus on human brain

Melcangi RC, Panzica G, Garcia-Segura LM.

Neuroscience. 2011 Sep 15;191:1-5. doi: 10.1016/j.neuroscience.2011.06.024. Epub 2011 Jun 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias